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ACS: Acute coronary syndrome 
AP: Action potential 
APA: Amplitude of action potential 
APD10: Action potential duration at 10% repolarization 
APD50: Action potential duration at 50% repolarization  
APD90: Action potential duration at 90% repolarization 
AR: Adrenoceptor 
ARVC: Arrhythmogenic right ventricular cardiomyopathy 
Chele: Chelerythrine chloride 
Clonidine: Clonidine hydrochloride 
CPVT: Catecholaminergic polymorphic ventricular tachycardia  
DCFH-DA: 2′,7′-dichlorodihydrofluorescin diacetate 
DCFH: Dichlorofluorescin 
DCF: Fluorescent dichlorofluorescein 
DPI: Diphenyleneiodonium chloride 
ECCs: Embryonic carcinoma cells 
EF: Ejection fraction 
EGCs: Embryonic germ cells 
Epi: Epinephrine  
ESCs: Embryonic stem cells 
FACS: fluorescence-activated cell sorting  
GPCR: G-protein coupled receptor 
hERG: human ether-a-go-go related gene 
ICa-L: L-Type calcium channel current 
INa: Sodium channel current 
INa-P: Peak sodium channel current 





INCX: Na+/Ca2+ exchanger current 
Ikr: Rapidly activating delayed rectifier potassium channel current 
Iks: Slowly activating delayed rectifier potassium channel current 
iPSCs: Induced pluripotent stem cells 
Iso: Isoprenaline 
Ito: Transient outward potassium current 
LQTs: long QT syndrome  
LV: Left ventricle  
mRNA: messenger RNA 
MYH: Myosin heavy chain 
MYL: Myosin light chain 
NAC: N-Acetyl-L-cysteine 
PCR: Polymerase chain reaction 
Pheny: (R)-(-)-Phenylephrine hydrochloride 
Phent: Phentolamine methanesulfonate salt 
PMA: Phorbol 12-myristate 13-acetate 
Prazo: Prazosin hydrochloride 
ROS: reactive oxygen species 
RP: Resting potential 
STEMI: ST-elevation myocardial infarction 
TTC: Takotsubo cardiomyopathy 
TTS: Takotsubo syndrome 
TNNT2: Troponin T2 










1.1. Takotsubo cardiomyopathy 
Takotsubo cardiomyopathy (TTC), which is also called Takotsubo syndrome 
(TTS) or stress cardiomyopathy, is a stress-associated cardiac disorder. TTS, 
which often mimicked an acute myocardial infarction with severe left 
ventricular dysfunction, was first described by Japanese authors in the 1990s 
[1, 2]. The typical feature is regional left ventricular wall motion abnormality 
(LVWMA), presenting an unusual appearance of the left ventricle with a 
narrow neck and apical ballooning during systole [3].The disease was named 
as ”Takotsubo” because the shape of the left ventricle during systole 
resembles a Japanese octopus-fishing pot. “Tako” means octopus and “Tsubo” 
means pot. TTC-patients often display clinical presentations such as chest 
pain, dyspnoea, syncope, ST-segment elevation, T-wave inversion, regional 
dyskinesia or akinesia, which are indistinguishable from a myocardial 
infarction [4, 5]. However, TTC is different from acute coronary syndromes, 
exhibiting that the coronary angiography usually shows no coronary artery 
stenosis, the left ventricular dysfunction extends beyond the area covered by a 
single coronary artery and recovers within days or weeks when appropriately 
treated [6].  
Since the first description of TTS, increasing cases have been recognized 
worldwide. The prevalence of TTC is estimated to be approximately 1–3% [7, 8] 
of all and 5–6% [9] of female patients that are suspected with ST-Elevation 
Myocardial Infarction (STEMI). A study using The Nationwide Inpatient Sample 
discharge records for the year 2008 reported a prevalence of 0.02% of 
hospitalized patients in the United States [10]. The recurrence rate of TTC is 





between 67–70 years, and about 80% are older than 50 years [11]. Women 
older than 55 years have a 10-fold higher risk than men [10] . 
TTC was originally considered a benign disease [12] . Later studies suggested 
that the severity of TTC is probably underestimated [3]. Although most patients 
have a good long-term prognosis, many complications can occur during the 
acute phase of the disease and the most frequent acute complication is heart 
failure [4]. About 30% of patients may display life threatening events including 
pulmonary oedema, cardiogenic shock and ventricular arrhythmias [13]. Long 
QT interval and torsades de pointes ventricular arrhythmias were frequently 
observed in affected patients [14]. Apical thrombus formation, cardioembolic 
stroke, left ventricular free wall rupture, and pericarditis were also reported [15]. 
Both short-term and long-term mortality are higher than previously estimated 
[16]. Indeed, it was reported the mortality during the acute phase in 
hospitalized patients is around 4% to 5%, similar to that of STEMI [17]. Further, 
it was shown that the mortality in TTC-patients after hospital discharge was 
higher than that in an aged-matched healthy population although the LV 
function recovered and no significant coronary disease was detected [18]. The 
mean in-hospital mortality of TTC was reported as 4.5% [19]. Recently, a study 
in a large number of patients (n=1750) reported a 30-day mortality of 5.9% and 
a long-term death rate of 5.6% per patient per year [11]. 
Although more and more TTC cases are diagnosed due to an increased 
awareness and recognition of the multiple clinical features of the disease, the 
pathogenesis of TTC has not been clearly clarified. At present, different 
mechanisms have been supposed: (1) Multi-vessel coronary artery spasm; (2) 
Coronary microvascular dysfunction (CMD); (3) Aborted myocardial infarction 
caused by transient thrombotic occlusion of a long wrap-around left anterior 
descending artery; (4) Obstruction of left ventricular outflow tract; (5) Cardiac 





Switch of ß-adrenoceptor signaling from Gs- to Gi-signaling, leading to 
ventricular wall motion abnormality; (8) Hypoplastic branching of the coronary 
arteries in the apical region of the heart, which may contribute to the local 
ventricular wall motion abnormality; (9) Regional differences in ß-adrenergic 
receptor density and sympathetic innervations [20]. Among those supposed 
mechanisms, most are questionable, but the widely accepted central actor 
contributing to the pathogenesis of TTC is the catecholamine excess, either 
from circulation or from local sympathetic nerve endings in the heart. Most 
patients with TTC experienced various stresses before an attack, such as the 
unexpected death of a relative or lover, the suppression of terror, the 
occurrence of a natural disaster, or severe physical stress, which often leads 
to emotional or psychological stress [6]. Therefore, TTC is also called “Heart 
Broken Syndrome” [3]. Recently, it was shown that TTC can also happen after 
a positive life event. So the name “happy heart syndrome” was also suggested 
for TTC [21]. Moreover, tests showed that serum catecholamine levels were 
elevated in more than 70% of TTC patients [22]. Strikingly, researchers found 
that plasma levels of catecholamines (adrenaline, norepinephrine, and 
dopamine) were several times higher in patients with TTC than in patients with 
STEMI (ST-Elevation Myocardial Infarction) during the acute phase, 
meanwhile myocardial levels of catecholamines also increased, and both 
levels stayed significantly high even one week after the onset of symptoms 
[22]. In addition, recent clinical cases have showed that some patients 
developed TTC after being injected subcutaneously with a large dose of 
epinephrine [23-26]. Studies in murine model have shown that injected high 
concentrations of epinephrine can produce reversible apical LV ballooning 
expansion and abnormal contractions similar to those in patients with TTC [27]. 
Taking together, increasing evidences indicate a contribution of catecholamine 





Since beta-adrenoceptors play important roles for heart function and TTC is 
related with catecholamine excess, administration of beta-blockers is a logical 
pharmacotherapy for TTC-treatment. Indeed, beta-blockers are commonly 
prescribed for some TTC-patients. Besides beta-blockers, treatments for TTC 
often contained emotional or physical stress relief, application of 
anticoagulants, angiotensin-converting enzyme inhibitors or aldosterone 
receptor blockers or angiotensin receptor blockers and statins in clinical 
practice [28, 29]. A beta-blocker may protect cardiomyocytes from toxic effects 
of high concentration of catecholamine. Actually, TTC-patients who were 
treated with conventional beta-blockers upon admission had a 59.6% relapse 
after discharge, and most of them received beta1-selective compounds 
(84.6%) [30]. Strikingly, a study reported that application of beta-blocker during 
the acute phase of TTC showed no benefits regarding the in-hospital mortality 
in patients with or without left ventricular outflow tract obstruction [31]. Another 
study reported that the application of beta-blockers in TTC-patients after 
discharge showed no beneficial effect on mortality after 1 year of follow-up [11]. 
Furthermore, no benefit of beta-blockers in preventing recurrence of TTC was 
detected in two meta-analyses [19, 32]. All of these evidences may suggest 
that mechanisms other than beta-receptor mediated signaling contribute also 
to the pathogenesis of TTC. Of note, previously reported studies focused on 
roles of the beta-adrenoceptor related signaling for the pathogenesis of TTC. 
Studies on non-beta-adrenoceptor signaling for occurrence of TTC remain 
spars. 
It is known that alpha-adrenoceptors exist in cardiomyocytes [33] . Animal 
experiments show that direct activation of cardiac alpha- and 
beta-adrenoceptors induced angina-like change (ST segment elevation) [34]. 
A study in rats showed that the alpha 1-receptor agonist phenylephrine 
induced TTC-like heart dysfunctions [35]. Another study demonstrated that 





for 30 minutes and then injected with the α2-AR agonist xylazine, the cardiac 
ejection fraction and the movement of the anterior wall were suppressed, 
whereas posterior wall movement was preserved, similar to TTC-phenotype 
[36], suggesting contribution of alpha-adrenoceptor signaling to occurrence of 
TTC. In addition, studies in rats showed that combining prazosin with 
metoprolol or amoxolol can eliminate stress-induced tachycardia and 
ST-segment elevation, which shows that simultaneous inhibition of α1- and 
β1-adrenergic receptors have a certain effect on the suppression of stress 
cardiomyopathy [34, 37]. It is a pity that all the studies that showed a 
contribution to alpha-adrenoceptor to TTC did not clarify which signaling or 
mechanism mediated the contribution of an alpha-adrenoceptor activation to 
the pathogenesis or arrhythmogenesis.   
Moreover, in a case of catecholamine-induced myocardial damage, the patient 
treated with beta-blocker propranolol worsened symptoms and even 
developed seriously heart failure, but re-administration of alpha-blockers 
relieved the symptoms [38]. Given the findings from animal and human studies, 
treatment with a combined alpha- and beta-blocker might be reasonable for 
some TTC-patients [39]. Taken all together, data suggest that -adrenoceptor 
signaling can take part in TTC-pathogenesis and blocking -adrenoceptors 
may have therapeutic benefits for TTC-patients.  However, studies on 
-adrenoceptor mediated signaling in human cardiomyocytes from 
TTC-patients or in the setting of TTC are still lacking. The importance of 
alpha-adrenoceptor signaling for LQTs and occurrence of arrhythmias under 
circumstances of TTC is still unknown.  
1.2. Induced pluripotent stem cells 
Embryonic stem (ES) cells derived from the inner cell mass of mammalian 
blastocysts not only have the ability to grow indefinitely but also maintain 





Therefore, in the past, people often used ES cells to build various disease 
models, further understand the disease mechanism, screen effective and safe 
drugs, and treat various diseases and injuries [41]. However, the ethical 
controversy over the use of human embryos and tissue rejection after patient 
transplantation limited the use of human ES cells. Generating pluripotent cells 
directly from patient-specific somatic cells can solve these problems [42]. In 
2006, Takahashi K and Yamanaka S successfully generated pluripotent stem 
cells from mouse adult fibroblasts through overexpression of identified factors 
[42]. They introduced four factors Octct3 / 4, Sox2, c-Myc and Klf4 (also called 
Yamanaka factors) under ES cell culture conditions, and successfully induced 
adult fibroblasts to differentiate into pluripotent stem cells. These cells, called 
iPS (induced pluripotent stem cells), have the morphological and growth 
characteristics of ES cells and express ES cell marker genes [42]. 
In 2007, with the same four factors: Oct3/4, Sox2, Klf4, and c-Myc, Takahashi 
et al successfully reprogrammed adult human dermal fibroblasts (HDF) from 
facial dermis of 36-year-old Caucasian female to pluripotent stem cells (first 
human iPS cell) [43]. Further testing revealed that human iPS cells were 
similar to human embryonic stem (ES) cells. Each induced pluripotent cell had 
a morphology and karyotype similar to that of human ES cells [44]. The 
epigenetic status and telomerase activity of each human induced pluripotent 
cell-specific gene are similar to that of human embryonic stem (ES) cells [43, 
44]. Furthermore, in vitro, these cells also could differentiate into cell types of 
the three germ layers as ES cells.  
In 2008, Genta Narazaki and colleagues successfully differentiated mouse 
iPSCs into cardiomyocytes [45] . Since then, numerous studies using iPS 
cell-derived cardiomyocytes (iPSC-CMs) have been published, demonstrating 
that iPSC-CMs possess features similar to adult cardiomyocytes. Importantly, 





recapitulate phenotypic features of heart diseases such as long- and short-QT 
syndromes [46, 47], Brugada-syndrome [48],  arrhythmogenic right 
ventricular cardiomyopathy (ARVC) [49], catecholaminergic polymorphic 
ventricular tachycardia (CPVT) [50], hypertrophic and dilated cardiomyopathy 
[51]. Therefore, hiPSC-CMs provide a good platform for studies on human 
cardiomyocytes, including physiology, pathophysiology and drug screening.  
1.3. Takotsubo cardiomyopathy disease models 
In the past, many studies have used a single dose of the selective 
β-adrenergic agonist isoprenaline (Iso) to induce a Takotsubo-like (TTC-like) 
model in mice [52]. But isoprenaline is only an agonist of the β receptor, and it 
is very limited to study the effects of other adrenoceptors on 
TTC-pathogenesis. Redfors et al. showed that not only isoprenaline but also 
epinephrine could induce TTC-like cardiac dysfunction in rats [35]. Paur et al 
established an in vivo animal model  of epinephrine-induced TTC that 
recapitulated the apical inhibition of the heart contraction and the reversibility 
of this cardiac inhibition [27].  
Although TTC models have been successfully established in animals, animal 
models are not ideal for simulating human diseases. The differences between 
animal and human being lead to limitations of animal studies. Human adult 
cardiomyocytes are ideal for studies on human cardiac disorders. However, 
the limited availability of human cardiomyocytes, especially the ventricular 
cardiomyocytes, is a major obstacle for studying human heart disease 
including TTC. Therefore, hiPSCs provide an opportunity to establish cellular 
models of human cardiac disorders. Recently, our group successfully 
generated hiPSC-CMs from healthy donors and investigated the toxic effects 
of high concentration of isoprenaline mimicking the setting of TTC [34]. 
Another group successfully generated hiPSC-CMs from two TTC-patients and 





isoprenaline challenge when compared with hiPSC-CMs from healthy donors 
[53]. Both studies indicate that TTC-phenotypic features were successfully 
modeled by hiPSC-CMs and this model can be useful for studying 
pathogenesis of TTC. 
In summary, so far available data suggest that alpha-adrenoceptors may 
contribute to pathogenesis of TTC, but the detailed intracellular signaling that 
mediated the effects of alpha-receptor activation in the setting of TTC (high 
concentration of catecholamine) has not been clarified. The roles of 
alpha-receptor signaling for long QT interval and arrhythmias caused by high 
and toxic concentration of catecholamine and the underlying ionic 
mechanisms are still unknown.  
1.4. Aims of the study 
Based on previous data demonstrating that (1) activation of sympathetic 
nerves and catecholamine excess play an important role for pathogenesis of 
TTC and (2) both -and -adrenoceptor blockers attenuated TTC phenotypic 
changes, we hypothesize that (1) -adrenoceptor signaling may contribute to 
ion channel dysfunctions caused by toxic effects of high concentration of 
catecholamine, (2) -adrenoceptor signaling may contribute to the long QT 
interval and occurrence of arrhythmias in the setting of high concentration of 
catecholamine. 
The purposes of this study were to use hiPSC-CMs for: (1) examining the 
involvement of -adrenoceptor signaling in alterations of ion channel functions 
and action potentials caused by toxic concentration of catecholamine, (2) 
assessing possible roles of the -adrenoceptor signaling for the occurrence of 
arrhythmias caused by toxic concentration of catecholamine and (3) exploring 
possible mechanisms underlying the -adrenoceptor mediated changes in the 





2. METHODS AND MATERIALS 
2.1. Ethics statement 
The skin biopsies from 3 healthy donors were obtained with written informed 
consent. The study was approved by the Ethics Committee of Medical Faculty 
Mannheim, University of Heidelberg (approval number: 2018-565N-MA) and 
conducted in accordance with the Helsinki Declaration of 1975 
(https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/), 
revised in 2013. 
2.2. Study design 
To investigate possible roles of -adrenoceptor signaling in arrhythmogenesis 
in TTC, the following experiments were designed (Figure 1): 
1) Assessment of toxic effects of high concentration of epinephrine (500 
µM) on action potentials and occurrence of arrhythmias in hiPSC-CMs. 
2) Assessment of the involvement of -adrenoceptor signaling in 
epinephrine effects by application of different -adrenoceptor blockers 
and agonists. 
3) Assessment of roles of activation of -adrenoceptor signaling on 
currents and expression levels of ion channels responsible for abnormal 
action potentials and arrhythmias. 







Figure 1. Study design of experiments. 
2.3. Generation of hiPSC-CMs 
Skin fibroblasts from three healthy donors (here named as D1, D2 and D3) 
were used for generation of iPS cells. D1 and D3 are female, while D2 is male. 
The generation of iPS cells from the fibroblasts was performed by Dr. 
Cyganek ś group (the Stem Cell Unit, Clinic for Cardiology and Pneumology, 
University Medical Center Göttingen, Germany) and described in our previous 
studies[54-56].  
The generated hiPS cell (hiPSC) lines from the three healthy donors were 
differentiated into cardiomyocytes (hiPSC-CMs) as described in our previous 
studies [54-56]. Briefly, culture dishes and wells were coated with Matrigel 
(Corning). The culture medium of hiPSCs was TeSR-E8 (Stemcell 
Technologies) and the cardiac medium for hiPSC-CMs was RPMI1640 
Glutamax (Life Technologies) consisting of 1% sodium pyruvate, 1% 





Technologies). During the first two weeks, CHIR99021 (Stemgent), BMP-4 
(R&DSystems), FGF-2 (MiltenyiBiotec), Activin A (R&D Systems), and IWP-4 
(Stemgent) were added at different times to induce the cells to differentiate into 
hiPSC-CMs. During the third week the selection medium which contained 
sodium lactate (Sigma, Germany) and RPMI medium without glucose and 
glutamine (WKS, Germany) was used to select cardiomyocytes. At 30 to 60 
days of differentiation, the cells were cultured with basic cardiac medium. After 
60 days of differentiation, the cardiomyocytes were dissociated from 6 well 
plates and used for PCR, immunofluorescence, flow cytometry analysis, or 
plated on Matrigel-coated 3.5 cm petri dishes as single cells for patch clamp 
test. 
The protocols for differentiation of iPS cells into cardiomyocytes are from the 
lab of Dr. Cyganek and Prof. Zimmermann in University of Göttingen. Using 
the same protocols, three clones of each cell line were alternately 
differentiated into hiPSC-CMs and data from all the three clones were 
combined for a cell line. At least 2 individual differentiation experiments of 
each clone were used for data analysis.  
After differentiation, the differentiation efficiency of iPSC-CMs was determined 
by flow cytometry analysis using an antibody against cardiac cTnT (TNNT2). A 
successful differentiation resulted in a purity of more than 90% of 
cardiomyocytes. Differentiation efficiency was also determined by observation 
of contracting cells and only cultures covered with greater than 90% 
contracting areas were used for further experiments. Importantly, no significant 
difference in the differentiation efficiency was detected among different cell 
lines.  
The success of the differentiation of cardiomyocytes was confirmed by 





and cTnT and the cardiac action potentials, which are different from that in 
other types of cells including smooth and skeletal muscle cells.    
2.4. Polymerase chain reaction assays 
Quantitative polymerase chain reaction assays (qPCR) was performed 
following the protocol and using the RNeasy mini kit (Qiagen, Hilden, Germany) 
to extract total RNA. The extracted RNA (10 μl) was reverse transcribed into 
cDNA using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher) 
on a Stratagene MX 3005P Real-Time Cycler (Stratagene, USA). Real-time 
quantitative PCR analysis was performed in the presence of sense and 
antisense primers (each 400 nM) using a quantitative SYBR Green PCR kit 
(SibirRox Hot Mastermix, Bioron, Germany) on StepOnePlus Real-Time PCR 
Systems (Thermo Fisher). 
The relative mRNA expression level is calculated as follows: According to the 
threshold cycle (CT), the ΔΔCT method is used to calculate the mRNA 
expression of the target gene relative to the housekeeping gene GAPDH in a 
sample of treated or untreated (control) cells, as a fold change = 2-Δ (ΔCT), 
where ΔCT = CTgene of interest-CTGAPDH and Δ (ΔCT) = ΔCT treated-ΔCT 
control [57]. To ensure reproducibility, the control and treatment groups were 
repeated three times independently. Each sample was given into two wells as 
a technical replicate to repeat the measurements. Statistics using mean ± 
SEM method. 
2.5. Patch-clamp 
The hiPSC-CMs on day 60 to day 80 were washed with PBS (w / o Ca, Mg) 
and incubated with 0.05% Trypsin-EDTA (Life Technologies) for 10 min at 
37 °C. Then RPMI medium + 10% FBS was added and pipetted up and down 
to obtain single cells. The cell suspension was centrifuged at 250 × g for 4 min 





with SF (cardiac medium + B27 + ASC). For patch-clamp experiments, the 
density of cells in the dish was 2-4 × 104. 
We used standard whole-cell patch-clamp recording techniques (Figure 2) to 
record different ion channel currents including the sodium (INa), L-type calcium 
(ICa-L), transient outward potassium (Ito), rapidly activating delayed rectifier 
potassium (IKr) current and action potential (AP) at room temperature. 
Furthermore, we used some specific channel blockers and different solutions 
or protocols to isolate a type from other types of ion channel currents. To 
minimize the influence of the rundown of recorded currents on the 
experimental results, we usually started the recordings after the current or AP 
was stabilized (3-5 minutes after the whole cell configuration was established). 
The patch electrode used for AP and current measurements was pulled from 
borosilicate glass capillary (MTW 150F; World Precision Instruments, Sarasota, 
FL) by the DMZ universal puller (Zeitz-Instrumente Vertriebs GmbH, Martin 
Reed, Germany) and filled with pre-filtered pipette solution (see below). The 
pipette resistance range for measuring currents was 2–4 MΩ and for 
measuring APs was 4-5 MΩ.  
After the patch pipette was carefully moved on the cell membrane by a 
micromanipulator (Figure 2A-B), a slight suction (negative pressure) was given 
to obtain high-resistance (Giga-Ohm) seal between cell membrane and the 
pipette wall (also called Giga-seal, Figure 2C), and then further suction was 
applied to rapture the membrane that was sucked into the pipette and 
establish a whole cell configuration (Figure 2D). Before the membrane 
capacitance was compensated, a voltage pulse of 10 ms from -80 mV to -85 
mV was given to record the capacitance transient current. Signals were 
acquired at 10 kHz and filtered at 2 kHz with the EPC10 Patch-master digitizer 
hardware (HEKA Germany) and Fit-master software (HEKA Germany). The 





capacitance in pF by dividing the area under capacitance current by 5. All the 
measured ion channel currents were normalized to the membrane capacitance 
to gain current densities in pA/pF. The current density is plotted against the 
respective voltages to produce a current-voltage (I-V) relationship curves.  
 
 
Figure 2. Establishment of whole-cell configuration of patch clamp recordings. 
APs were measured in current-clamp mode (CC-mode). Spontaneous APs 
were recorded at CC-mode without stimulations. The frequency and 
arrhythmic events such as irregular beatings, early after depolarizations, 
delayed after depolarizations and trigger activities were analyzed if they 
occurred during recordings.  
For recording APs paced at a fixed frequency, a short current pulse (2 ms, 1nA) 
was applied at 1 Hz to trigger the action potentials. The AP parameters 
including the resting potential (RP), AP amplitude (APA), the maximal velocity 
of depolarization (Vmax), the AP duration at 10% repolarization (APD10), the 
AP duration at 50% repolarization (APD50) and the AP duration at 90% 





      
 
Figure 3. Analysis of action potential parameters. 
The extracellular solution for recording APs and transient outward potassium 
channel (Ito) currents contained 127 mmol/L NaCl, 5.9 mmol/L KCl, 2.4 mmol/L 
CaCl2, 1.2 mmol/L MgCl2, 11 mmol/L glucose, and 10 mmol/L HEPES. The pH 
value was adjusted to 7.4 with NaOH. 1 umol/L nifedipine, 1 umol/L E-4031, 
and10 umol/L TTX were added to block the ICa-L, IKr, and INa, respectively when 
transient outward potassium current (Ito) was recorded. The intracellular 
solution comprised 6 mmol/L NaCl, 126 mmol/L KCl, 1.2 mmol/L MgCl2, 
5 mmol/L EGTA, 11 mmol/L glucose, 10 mmol/L HEPES and 1 mmol/L 
Mg-ATP. The pH value was adjusted to 7.2 with KOH.   
The extracellular solution for rapidly activating delayed rectifier potassium (IKr) 





HEPES. The pH value was adjusted to 7.4 with CsOH. The intracellular 
solution was the same as the extracellular solution.  
The extracellular solution for peak sodium current measurements contained 20 
mmol/L NaCl, 130 mmol/L CsCl, 1.8 mmol/L CaCl2, 1 mmol/L MgCl2, 10 
mmol/L Hepes, 10 mmol/L glucose, 0.001 mmol/L nifedipine. The pH value 
was adjusted to 7.4 with CsOH. The extracellular solution for late sodium 
current measurements contained 135 mmol/L NaCl, 20 mmol/L CsCl, 1.8 
mmol/L CaCl2, 1 mmol/L MgCl2, 10 mmol/L Hepes, 10 mmol/L glucose, 0.001 
mmol/L nifedipine, pH 7.4 (CsOH). The intracellular solution for peak and late 
sodium current contained 10 mmol/L NaCl, 135 mmol/L CsCl, 2 mmol/L CaCl2, 
3 mmol/L Mg-ATP, 5 mmol/L EGTA, 10 mmol/L HEPES, pH 7.2 (CsOH). 
The extracellular solution for L-type calcium channel current (ICa-L) 
measurements contained 140 mmol/L TEA-Cl, 5 mmol/L CaCl2, 1 mmol/L 
MgCl2, 10 mmol/L HEPES, 10 mmol/L glucose, pH 7.4 (CsOH). The 
intracellular solution contained 10 mmol/L NaCl, 135 mmol/L CsCl, 2 mmol/L 
CaCl2, 3 mmol/L Mg-ATP, 5 mmol/L EGTA, 10 mmol/L HEPES, pH 7.2 
(CsOH). 
The extracellular solution for Na+/Ca2+ exchanger current (INCX) measurements 
contained 135 mmol/L NaCl, 10 mmol/L CsCl, 2 mmol/L CaCl2, 1 mmol/L 
MgCl2, 10 mmol/L HEPES, 10 mmol/L glucose, 0.01 mmol/L nifedipine, 
0.1 mmol/L niflumic acid, 0.05 mmol/L lidocaine, and 0.02 mmol/L 
dihydroouabain (pH 7.4 (CsOH)). The intracellular solution contained 1 mmol/L 
MgCl2, 115 mmol/L CsCl, 1 mmol/L CaCl2, 10 mmol/L NaCl, 3 mmol/L Mg-ATP, 
and 5 mmol/L EGTA, 20 mmol/L TEA-Cl, 10 mmol/L HEPES, pH 7.2 (CsOH). 
2.6. Flow cytometry 
The ROS production in hiPSC-CMs was evaluated by 2′,7′-Dichlorofluorescin 





instructions. DCFH-DA is a non-polar fluorescence probe that can penetrate 
cell membranes, where it is converted into DCFH and then detected by flow 
cytometry. The cardiomyocytes were incubated with 300 µl (150 U) 
collagenase CLS I (Worthington, Germany) for 40 min at 37 °C, and then 
washed with PBS and incubated with 0.05% Trypsin-EDTA (Life Technologies) 
for 2-4 min at 37 °C. After adding RPMI medium containing 10% FBS, these 
cells were centrifuged at 250 × g for 4 min at room temperature. Next the 
supernatant was discarded and the cells was resuspended in basic culture 
medium. The cells were plated into the 15ml tubes at a density of 1 × 104 
cells/tubes and incubated with 10 μM DCFH-DA at 37°C for 30 minutes in the 
dark. After the cells were washed 3 times with PBS, they were measured on 
BD FACSCanto™ II (Becton Dickinson, Heidelberg, Germany). Analysis was 
performed using a quantitative method via BD FACS Diva software (Version 
8.0.1). 
2.7. Immunofluorescence (IF) staining 
The cardiomyocytes were incubated with 0.05% Trypsin-EDTA (Life 
Technologies) for 2-4 min at 37 °C. After adding RPMI medium containing 10% 
FBS, these cells were centrifuged at 250 × g for 4 min at room temperature. 
Next, the supernatant was discarded and the cells was resuspended in basic 
culture medium and pipetted onto culture slides (FALCON 354114). After 
slides stayed overnight, they were washed with PBS 2-3 times, and then fixed 
with 4% paraformaldehyde (Sigma) at RT for 20 min. After washed with PBS 
2-3 times, cells were permeabilized with 0.1% Triton-X100 (Carl Roth) for 10 
min. Then they were washed with PBS 2-3 times and blocked with 5% bovine 
serum albumin (BSA; Sigma-Aldrich) in PBS at 4°C for 1 h. Primary antibodies 
were applied in 5% BSA overnight at 4°C. Cells were then washed with PBS 
and incubated for 1 h at room temperature with corresponding secondary 





washed with PBS, incubated with DAPI (Biozol) for 10 min at RT in the dark. 
Images were collected using the confocal microscope TCS SP-8 upright (Leica, 
Germany) with Plan-Apochromat 40×/0.6 objective. 
2.8. Materials (primers, antibodies, kits and substances) 
Table 1. Reagents and substances.  
Kits and substances Company 
RNeasy Mini Kit (250) Qiagen 
High-Capacity cDNA Reverse Transcription Kit Thermo Fisher 
SibirRoxHot Master Mix, ROX 0.1μM   Bioron 
VECTASHIELD with DAPI 10 ml Biozol 
Phentolamine methanesulfonate salt Sigma 
N-Acetyl-L-cysteine Sigma 
2′,7′-Dichlorofluorescin diacetate Sigma 
Clonidine hydrochloride Sigma 
(R)-(−)-Phenylephrine hydrochloride Sigma 
H2O2  (30%) Merck 
(±)-Epinephrine hydrochloride Sigma 
Chelerythrine chloride Sigma 
Prazosin hydrochloride Sigma 
 
Table 2. Primer sequences for real-time polymerase chain reaction 
(PCR).  
Primer Company 
Hs_ADRA1A_1_SG QuantiTect Primer Assay Qiagen 
Hs_ADRA2A_1_SG QuantiTect Primer Assay Qiagen 
Hs_CACNA1C_1_SG QuantiTect Primer Assay Qiagen 





Hs_SCN10A_1_SG QuantiTect Primer Assay Qiagen 
Hs_KCNH2_2_SG QuantiTect Primer Assay Qiagen 
Hs_KCNQ1_1_SG QuantiTect Primer Assay Qiagen 
Hs_KCND3_1_SG QuantiTect Primer Assay Qiagen 
Hs_SLC8A1_1_SG QuantiTect Primer Assay Qiagen 
Hs_GAPDH_1_SG QuantiTect Primer Assay Qiagen 
G protein alpha S / GNAS qPCR Primer Pairs, Human Sino Biological Inc. 
       
Primer   Direction Sequence  Size (bp) 
GNAI2 forward 5'-CTTGTCTGAGATGCTGGTAATGG-3' 23 
 
reverse 5'-CTCCCTGTAAACATTTGGACTTG-3' 23 
    
GNAQ forward 5'-GACTACTTCCCAGAATATGATGGAC-3' 25 
 
reverse 5'-GGTTCAGGTCCACGAACATC-3' 20 
    
GNA11 forward 5'-GATCCTCTACAAGTACGAGCAGAAC-3' 25 
  reverse 5'-ACTGATGCTCGAAGGTGGTC-3' 20 
 
 
Table 3. Antibody for Immunofluorescence (IF) staining. 
Antibody Company 
Alexa Fluor® 647 Mouse Anti-Cardiac Troponin T BD Biosciences 
Anti-alpha 1 Adrenergic Receptor/ADRA1 antibody Abcam 
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed 
Secondary Antibody, Alexa Fluor Plus 488 Thermofisher 
Chromeo™ 642 Goat anti-Rabbit IgG Active Motif 







All data are shown as mean ± SEM and were analyzed using SigmaPlot 14.0 
(Systat GmbH, Germany). By analyzing the data with the Kolmogorov Smirnov 
test, it was decided whether parametric or non-parametric tests were used for 
analysis. The t-test was used for comparisons of two independent groups with 
normal distribution. For parametric data one-way ANOVA with Holm-Sidak 
post-test for multiple comparisons (all treated groups versus control) were 
performed. For non-parametric data the Kruskal-Wallis test with Dunn’s 
multiple comparisons post-test was used. To compare categorical variables, 
the Fisher-test was used. P < 0.05 (two-tailed) was considered significant. 
3. RESULTS 
3.1. Characterization of hiPSC-CMs 
Cardiomyocytes generated from hiPS-cells that were derived from skin 
fibroblasts of three healthy donors (D1, D2, D3) were used for the study. D1 
was used for the majority of the study. D2 and D3 were used for examining the 
individual variability in results. The successful generation of hiPSC-CMs from 
hiPSCs was confirmed by qPCR or immunostaining and FACS analysis of the 
expression of cardiac markers and showed in our recent publications [49]. In 
the current study, the cardiac marker cTnT (TNNT2) was examined again by 
immunostaining (Figure 4C) and FACS (Figure 10B). These data together with 
the cell beating and action potentials with cardiac morphology indicate the 








 Figure 4. PCR assay and immunofluorescence of alpha-adrenoceptor and G 
protein expression. mRNA levels are normalized with GAPDH as a housekeeping 
gene. (A) Expression level of mRNA for α1 (ADRA1A) and α2 (ADRA2A) 
adrenoceptors in hiPSC-CMs. (B) Expression level of mRNA for Gs (GNAS), Gi 
(GNAI2), Gq (GNAQ and GNA11) in hiPSC-CMs. (C) Confocal images of 
immunofluorescence staining of cTnT (green) and ADRA1 (red). The nucleus was 
stained by DAPI (blue). The “n” numbers represent experimental numbers. Scale bars: 
20 μm. cTnT: cardiac muscle troponin T, a marker of cardiomyocyte. 
 
3.2. Alpha-adrenoceptor and G protein expression in hiPSC-CMs 
To determine whether the α-adrenergic receptor and G protein are expressed 
in the differentiated hiPSC-CMs, we analyzed the mRNA levels of two 





Our data confirmed that the ADRA1A and ADRA2A α-adrenergic receptor 
isoforms exist in hiPSC-CMs (Figure 4A). Differential expression of adrenergic 
receptor associated proteins including Gq, Gi and Gs proteins could also be 
detected in differentiated hiPSC-CMs (Figure 4B). Furthermore, the 
localization of ADRA1A in 60- to 80-day-old hiPSC-CMs were analyzed using 
immunocytochemistry. ADRA1A is widely distributed but predominantly on the 
microtubule network and near cell membrane and nucleus (Figure 4C).  
3.3. The -adrenoceptor activation contributed to effects of epinephrine 
on ion channel expression 
To examine whether -adrenoceptors play important roles for ion channel 
dysfunctions in the setting of TTC, we first checked the expression profile of 
ion channels related to changing of the action potentials in hiPSC-CMs 
challenged by high concentration (500 µM) epinephrine (Epi). At the same time, 
we analyzed the effects of an -adrenoceptor blocker against the effects of Epi 
on ion channel expression levels (Figure 5).The expression levels of 
CACNA1C (coding L-type calcium channel), SCN10A (coding Nav1.8 sodium 
channel) and SLC8A1 (coding Na+/Ca2+-exchanger, NCX1) genes were 
elevated by Epi (Figure 5 A-C), but the expression of SCN5A (coding Nav1.5 
sodium channel), KCNH2 (coding IKr, also called HERG channel) and KCND3 
(coding Ito channel, Kv4.3) gene was reduced by Epi (Figure 5 D-F). Epi did not 
influence the expression level of KCNQ1 (coding IKs channels) (Figure 5 G). 
The -adrenoceptor blocker phentolamine (500 µM) prevented the Epi-effects 
on gene expression levels (Figure 5), suggesting the -adrenoceptor signaling 








Figure 5. Activation of alpha-adrenoceptor changed ion channel expression 
levels. hiPSC-CMs were treated for 1 h with either vehicle (Control) or 500 µM 
epinephrine (Epi) or epinephrine plus 500 µM phentolamine (Epi+Phent). qPCR 
analysis was performed to measure the expression levels of ion channels. (A) Mean 
values of L-type calcium channel (CACNA1C) expression. (B) Mean values of sodium 
channel (SCN10A) expression. (C) Mean values of Na+/Ca2+ exchanger (SLC8A1) 
expression. (D) Mean values of cardiac sodium channel (SCN5A) expression. (E) 
Mean values of transient outward K channel (KCND3, Ito) expression. (F) Mean values 
of rapidly activating delayed rectifier K (KCNH2, IKr) channel expression. (G) Mean 
values of slowly activating delayed rectifier K (KCNQ1, IKs) channel expression. “n” 
represents experimental numbers (biological replicates). *p<0.05 versus Control 






3.4. The -adrenoceptor activation contributed to toxic effects of 
epinephrine on action potentials 
To evaluate the contributions of -adrenoceptors to the toxic effects of 
catecholamine excess on cellular electrophysiology, we assessed the effects 
of epinephrine (500 µM,1 hour) on the action potential (AP) properties of 
cardiomyocytes. Epinephrine treatment did not change the RP (resting 
potential) and APA (amplitude of action potential), but reduced Vmax (maximal 
upstroke velocity) and prolonged APD10 (the action potential duration at 10% 
repolarization) from 11.32 ± 0.16 ms to 13.09 ±0.49 ms, APD50 (the action 
potential duration at 50% repolarization) from 128.26±28.40 ms to 
453.20+56.31 ms and APD90 (the action potential duration at 90% 
repolarization ) from 277.91±36.92 ms to 615.37± 62.79 ms, respectively 
(Figure 6). After treatment with phentolamine (Phent, 500 µM, a non-selective 
alpha receptor antagonist) in the presence of epinephrine, the effects of 
epinephrine were reversed (Figure 6A-E). Phentolamine alone had no effect 
on AP characteristic of hiPSC-CMs (Figure 6). These results indicate that 







Figure 6. Alpha-adrenoceptor signaling contributed to action potential changes 
by epinephrine. hiPSC-CMs were treated with either vehicle (Control) or 500 µM 
phentolamine (Phent) or 500 µM epinephrine (Epi) or epinephrine plus phentolamine 
(Epi+Phent) for 1 h. Action potentials (AP) were recorded at 1 Hz stimulation. (A) 
Representative traces of APs in control and epinephrine-treated hiPSC-CMs in the 
presence and absence of phentolamine. (B) Mean values of APD at 10% 
repolarization (APD10). (C) Mean values of APD at 50% repolarization (APD50). (D) 
Mean values of APD at 90% repolarization (APD90). (E) Mean values of maximal 
upstroke velocity of AP (Vmax). (F) Mean values of action potential amplitude (APA). 
(G) Mean values of resting potentials (RP). Values given are mean ± SEM. The 
numbers given in B represent the number of cells for B-G. *p<0.05 versus Control 
according to one-way ANOVA with Holm-Sidak post-test. 
3.5. The -adrenoceptor activation contributed to occurrence of 





The changes of APs may cause arrhythmias. Therefore, we tested the 
possible involvement of the -adrenoceptor activation in the arrhythmogenesis 
in setting of catecholamine excess. The same concentration of Epi (500 µM) 
was applied to spontaneously beating cells. The arrhythmic events including 
EAD (early afterdepolarization), DAD (delayed afterdepolarization), irregular 
beating or trigger activity were analyzed. The results showed a significantly 
increased frequency of the early after-depolarizations (EADs) (red arrow)-like 
phenomena and delayed after-depolarizations (DADs) (green arrow) -like 
phenomena and trigger activities (black arrows) in the epinephrine treatment 
group (Figure 7A and 7B). Interestingly, application of phentolamine (Phent, 
500 µM, a non-selective alpha receptor antagonist) suppressed the effect of 
Epi (Figure 7C).  
Statistical analysis showed that only 42% of the cells (6/14) in the control 
group showed arrhythmic events, whereas 100% of the cells (12/12) in the 
presence of epinephrine developed arrhythmia (Figure 7D). In the presence of 
phentolamine, there were still 85% of the cells (6/7) showing arrhythmias but 
the arrhythmic events were largely reduced (Figure 7D and F, Table 4). The 
Epi treatment slightly reduced the cells beating rate compared with control 
group, but it was not statistically significant (Figure 7E, Table 4). These data 
indicate that high concentration of catecholamines in cardiomyocytes could 








Figure 7. Alpha receptor blocker attenuated arrhythmic events induced by 
epinephrine. hiPSC-CMs were treated with either vehicle (Control) or 500 µM 
epinephrine (Epi) or epinephrine plus phentolamine (500 µM, Epi+Phent) for 1 h. 
Spontaneous action potentials were recorded in spontaneously beating hiPSC-CMs. 
The occurrence of arrhythmic events (irregular or triggered beats or EAD- or DAD-like 
events) was compared among the three cell groups. (A) Action potential traces 
obtained in a cell in the absence of epinephrine. (B) Action potential traces obtained in 
the presence of epinephrine (Epi) showing EADs (red arrows) and DADs (green 
arrows) and trigger activities (black arrows). (C) Action potential traces obtained in the 
presence of phentolamine and epinephrine (Phent+Epi). (D) Summary bar graph 
showing the effects of Epi and Phent regarding the number of cells showing 
arrhythmic events (%). (E) Summary bar graph showing the effects of Epi and Phent 
on the beating rate expressed in beats min−1 (bpm). (F) Summary bar graph showing 
the effects of Epi and Phent on the arrhythmic events (%). The numbers given in D 





number of cells. The numbers given in E represent the number of cells for E-F.  
*p<0.05 versus Control according to the Fisher-test (D) or one-way ANOVA with 
Holm-Sidak post-test (F). 
Table 4. Data from recordings of spontaneous action potentials of 
hiPSC-CMs. 
Group Control Epi Epi+Phent p value 
 




Number of Cells showing  
Arrhythmia  6 12 6 
 
 
Beating Rate (bpm） 25.79±3.22 19.92±3.58 23.71±3.64 >0.05 
 
Arrhythmic Events (%) 9.5%±4.26% 25.42%±5.41% 14.86%±4.51% ≤0.01 
 
Sinus rhythm Counts 209  277  199  
 
 
Arrhythmia Counts 28 81 26    
 
Epi: epinephrine; Phent: Phentolamine 
3.6. The 1-adrenoceptor activation contributed to effects of epinephrine 
on APs 
Because epinephrine can activate both α1- and α2-receptors and 
phentolamine is a non-selective α-receptor antagonist, we further used the 
α1-receptor selective agonists (phenylephrine ,100 µM, 1 h) and α2-receptor 
selective agonists (clonidine ,10 µM, 1 h), respectively, to clarify which 
alpha-adrenergic receptor mediated the Epi-effects on APs. Phenylephrine 
treatment did not change the RP (resting potential) and APA (amplitude of 
action potential), but reduced Vmax (maximal upstroke velocity) and prolonged 





(repolarization at 90%) significantly (Figure 8), similar to effects of Epi. After 
treatment with prazosin (Prazo,1 µM, a selective α1-receptor antagonist) in the 
presence of phenylephrine, the effect was reversed (Figure 8 B-E). In contrast, 
clonidine treatment showed no significant effect on AP characteristics of 
hiPSC-CMs (Figure 8). These data demonstrated that α1-adrenoceptor 




Figure 8. Effects of different alpha-adrenergic receptor agonists on action 
potentials of hiPSC-CMs. hiPSC-CMs were treated with vehicle (Control) or 100 µM 
phenylephrine (Pheny) or 100 µM clonidine or phenylephrine plus 100 µM prazosin 
(Pheny+Prazo) for 1 hour. APs were recorded with 1 Hz stimulation. (A) 
Representative traces of action potentials (AP) in hiPSC-CMs. (B) Mean values of 





(APD50). (D) Mean values of APD at 90% repolarization (APD90). (E) Mean values of 
maximal upstroke velocity of AP (Vmax). (F) Mean values of action potential 
amplitude (APA). (G) Mean values of resting potentials (RP). Values given are 
mean ± SEM. The numbers given in B represent the number of cells for B-G.  





3.7. ROS mediated the effects of the α-adrenoceptor activation 
Our previous study detected that beta-adrenoceptor activation contributed to 
the ROS (oxygen species) production in the presence of high concentration of 
isoprenaline [57], which led us to test our hypothesis that ROS may also 
mediate the effects of α-adrenoceptor activation in catecholamine excess. First, 
we checked the effects of a ROS blocker N-Acetyl-L-cysteine (NAC, 1 mM) on 
APs in presence of epinephrine or phenylephrine. Indeed, NAC attenuated and 
H2O2 (100 µM, the main form of endogenous ROS) mimicked the Epi- and 
Pheny-effects on APDs (Figure 9), suggesting involvement of ROS in effects 








Figure 9. ROS mediated the effects of epinephrine on action potentials. 
hiPSC-CMs were treated with either vehicle (Control) or 500 µM epinephrine (Epi) or 
100 µM phenylephrine (Pheny) or epinephrine plus 1 mM NAC, a ROS-blocker 
(Epi+NAC,) or phenylephrine plus NAC (Pheny+NAC) or 100 µM H2O2 (H2O2) or NAC 
alone for 1 h. Action potentials paced at 1 Hz were recorded. (A) Representative 
AP-traces of a cell from each group.  (B) Averaged values of APD10. (C) Averaged 
values of APD50. (D) Averaged values of APD90. (E) Averaged values of Vmax. (F) 
Averaged values of APA.  (G) Averaged values of resting potential (RP).   The 
numbers given in B represent the number of cells for B-G.  *p<0.05 versus Control 
according to one-way ANOVA with Holm-Sidak post-test. 
Then the ROS-production was assessed by FACS in cells with Epi and Epi 
plus phentolamine. The ROS-level was increased in Epi-treated cells (Figure 
10 C-E, H), suggesting that Epi may affect APs through ROS. Strikingly, the 
α-adrenoceptor blocker reduced the Epi-induced ROS production in cells 





activation to ROS production induced by catecholamine excess. H2O2 was 




Figure 10. Alpha blocker reduced ROS-production induced by epinephrine. 
hiPSC-CMs were treated with either vehicle (Control) or 500 µM epinephrine (Epi) or 
epinephrine plus 500 µM phentolamine (Epi+Phent) for 1 h. ROS-production was 
measured by FACS and quantified by measuring dichlorofluorescein fluorescence 
intensity with BD FACS Diva software (Version 8.0.1). (A) and (B) Representative 
FACS analyses of cTnT: cardiac muscle troponin T (a cardiomyocyte marker) 
expression in hiPSC-CMs. (C) and (D) Representative FACS analyses of ROS 
generation in control group. (E) Representative FACS analyses of ROS generation in 
the presence of epinephrine (Epi). (F) Representative FACS analyses of ROS 





Representative FACS analyses of ROS generation in the presence of H2O2 (100 µM). 
(H) Summary of ROS generation from samples in D, E, F and G. “blank” represents 
control measurements in cells without treatment of the ROS fluorescence dye. Values 
given are mean ± SEM. “n” represents experimental numbers (biological replicates). 
*p<0.05 versus Control according to one-way ANOVA with Holm-Sidak post-test. 
3.8. NADPH oxidases were involved in effects of 1-adrenoceptor 
activation 
Since ROS production is related to numerus intracellular signaling, we tried to 
identify a signaling factor responsible for the elevated ROS induced by 
activation of 1-adrenoceptors. Previous studies have demonstrated that in 
cardiovascular diseases, the production of reactive oxygen species (ROS) is 
related to the activation of NADPH oxidase [58]. Therefore, we used 
diphenyleneiodonium (DPI,10 µM), an inhibitor of NADPH oxidases, to treat 
cells in the presence of phenylephrine. We observed that the DPI exhibited 
significant inhibition on the effects of phenylephrine on APs. These data 
indicate that NADPH oxidases are involved in the activation of 







Figure 11. NADPH oxidases were involved in alpha 1-adrenoceptor activation. 
hiPSC-CMs were treated for 1 h with either vehicle (Control) or 100 µM phenylephrine 
(Pheny) or phenylephrine plus NADPH inhibitor 10 µM DPI (Pheny+DPI). Action 
potentials paced at 1 Hz were recorded. (A) Representative traces in a cell from each 
group. (B) Averaged values of APD10 from each group. (C) Averaged values of 
APD50 from each group. (D) Averaged values of APD90 from each group. (E) 
Averaged values of Vmax from each group. (F) Averaged values of APA from each 
group.  (G) Averaged values of resting potential (RP) from each group.   The 
numbers given in B represent the number of cells for B-G.  *p<0.05 versus Control 
according to one-way ANOVA with Holm-Sidak post-test. 
3.9. Protein kinase C (PKC) was involved in the effects of 
1-adrenoceptor activation 
Catecholamine mediated generation of ROS can result from the actions of a 






through PKC [59]. Hence, we examined the possible role of PKC for 
AP-changes. A PKC-inhibitor (chelerythrine, 10µM) suppressed not only the 
effects of Epi but also the effects of phenylephrine on APs (Figure 12 A-D). In 
addition, a PKC stimulator phorbol-12-myristate-13-acetate (PMA) exerted 
effects on APs similar to that of Epi and Pheny (Figure 12 A, B, D), implying 
that PKC is required for the effect of α-adrenoceptor activation. 
 
 
Figure 12. Protein kinase C was involved in alpha 1-adrenoceptor signaling. 





(Epi) or 100 µM phenylephrine (Pheny), and the epinephrine plus 10µM chelerythrine, 
an inhibitor of protein kinase C (Epi+Chele) or phenylephrine plus chelerythrine 
(Pheny+Chele) or 10 µM phorbol-12-myristate-13-acetate (PMA). Action potentials 
paced at 1 Hz were recorded. (A) Representative traces in a cell from each group. (B) 
Averaged values of APD10 from each group. (C) Averaged values of APD50 from 
each group. (D) Averaged values of APD90 from each group. (E) Averaged values of 
Vmax from each group. (F) Averaged values of APA from each group.  (G) Averaged 
values of resting potential (RP) from each group. The numbers given in B represent 
the number of cells for B-G.  *p<0.05 versus Control according to one-way ANOVA 
with Holm-Sidak post-test. 
3.10. Protein kinase C acted as a downstream factor of ROS 
Given that both ROS and PKC were involved in 1-adrenoceptor activation, 
we intended to reveal whether PKC is a downstream or upstream signaling of 
ROS in -adrenoceptor activation. Cells were challenged by H2O2 in presence 
and absence of the PKC-inhibitor (chelerythrine). The PKC-inhibitor did 
suppress the effects of H2O2 (Figure 13), suggesting that PKC acted as a 







Figure 13. Protein kinase C was a downstream factor of ROS. hiPSC-CMs were 
treated for 1 h with either vehicle (Control) or 100 µM H2O2 (H2O2) or H2O2 plus 10 µM 
chelerythrine (H2O2+Chele). Action potentials paced at 1 Hz were recorded. (A) 
Representative traces in a cell from each group. (B) Averaged values of APD10 from 
each group. (C) Averaged values of APD50 from each group. (D) Averaged values of 
APD90 from each group. (E) Averaged values of Vmax from each group. (F) 
Averaged values of APA from each group. (G) Averaged values of resting potential 
(RP) from each group. The numbers given in B represent the number of cells for B-G.  








3.11. The ionic mechanisms of AP-changes induced by -adrenoceptor 
activation 
To investigate the underlying ionic currents responsible for aforementioned 
APD changes, we evaluated the effects of epinephrine (Epi) or phenylephrine 
(Pheny) on different ion channel currents. First, the effects of Epi or Pheny on 
inward currents INa, ICaL, and INCX were checked in vehicle- (control) or Epi- or 
Pheny-treated cells. The peak INa (INa-p) was reduced by Epi (Figure 14 A, C, G). 
The late INa (INa-L), however, was slightly increased by Epi (Figure 14 B). 
Phentolamine (Phent) prevented the Epi effect on INa-p, suggesting 
-adrenoceptor activation may contribute to the inhibitory effect. Pheny was 
applied to stimulate 1-adrenoceptor. Indeed, Pheny mimicked Epi effect on 
INa-p (Figure 14 A, C, G), which confirmed the contribution of 1-adrenoceptor 
signaling to the inhibition of INa-p. Further, the sodium channel kinetic 
parameters were analyzed. Epi but not Pheny enhanced the 
voltage-dependent inactivation of the channel by shifting the inactivation 
curves (evaluated by the potential of 50% inactivation (V0.5)) to more negative 
potentials (Figure 14 E, I). Both Epi and Pheny failed to influence the activation 
and recovery from inactivation (Figure 14 D, H and F, J). Strikingly, the Epi 
effect on the inactivation was not reversed by the -adrenoceptor blocker 






Figure 14. Sodium channel currents was changed by alpha-adrenoceptor 
activation. hiPSC-CMs were treated for 1 h with vehicle (Control) or 500 µM 
epinephrine (Epi) or epinephrine plus 500 µM phentolamine (Epi+Phent) or 100 µM 
phenylephrine (Pheny). (A) Representative traces of sodium channel currents (INa). (B) 
Mean values of late INa in absence and presence of epinephrine (Epi). (C) I-V curves 
of INa-p from each group. (D) Activation curves of INa-p from each group. (E) Inactivation 
curves of INa-p from each group. (F) Time course curves of recovery from inactivation. 
(G) Mean values of INa-p at -35 mV. (H) Mean values of potentials at 50% activation 
(V0.5). (I) Mean values of potentials at 50% inactivation (V0.5). (J) Mean values of 
time constants (Tau) of recovery from inactivation. “n” represents number of cells. 
*p<0.05 versus Control according to the analysis of one-way ANOVA with Holm-Sidak 
post-test. 
 
The L-type calcium channel current (ICa-L) was significantly enhanced by Epi 
(Figure 15 A-B, F). The -adrenoceptor blocker (Phent) blocked and the 





indicative of roles of 1-adrenoceptor signaling for the enhancement of ICa-L. 
However, Epi and Pheny changed the channel kinetics differentially. Epi 
enhanced the channel activation significantly by shifting the activation 
(evaluated by the potential of 50% activation (V0.5)) to a more negative 
potential, without influencing the inactivation of ICa-L (Figure 15 C-D, G-H). 
While Pheny changed the channel activation only slightly but strongly 
enhanced the inactivation by shifting the inactivation curve to a more negative 
potential (Figure 15 C-D, G-H). Both Epi and Pheny failed to influence the time 




Figure 15. L-type calcium channel currents was changed by alpha-adrenoceptor 
activation. hiPSC-CMs were treated for 1 h with vehicle (Control) or 500 µM 
epinephrine (Epi) or epinephrine plus 500 µM phentolamine (Epi+Phent) or 100 µM 





(ICa-L). (B) I-V curves of ICa-L from each group. (C) Activation curves of ICa-L from each 
group. (D) Inactivation curves of ICa-L from each group. (E) Time course curves of 
recovery from inactivation. (F) Mean values of ICa-L at 10 mV. (G) Mean values of 
potentials at 50% activation (V0.5). (H) Mean values of potentials at 50% inactivation 
(V0.5). (I) Mean values of time constants (Tau) of recovery from inactivation. The 
numbers given in B-E represent the number of cells also for F-I, respectively.  
*p<0.05 versus Control according to one-way ANOVA with Holm-Sidak post-test. 
The Na+/Ca2+ exchanger current (INCX) can also influence APD. So, we 
checked whether it participated in the APD-prolongation induced by Epi. In 
hiPSC-CMs treated by Epi, INCX was only slightly enhanced, which did not 
reach the statistical significance (Figure 16). 
 
Figure 16. Na+/Ca2+ exchanger currents in the presence of epinephrine. 
hiPSC-CMs were treated for 1 h with vehicle (Control) or 500 µM epinephrine. NiCl2 (3 





from other currents. (A-B) Representative current traces in hiPSC-CMs treated with 
vehicle (Control) or epinephrine (Epi) in the absence (black line) and presence of 
NiCl2 (red line). (C) Representative traces of NiCl2-sensitive currents (INCX) in 
hiPSC-CMs treated with vehicle (Control) or epinephrine (Epi). (D) Mean values of 
INCX at 50 mV and -85 mV in absence (Control) and presence (Epi) of epinephrine. “n” 
represents number of cells.  
 
Next, we evaluated the outward K+ currents including the transient outward K+ 
currents (Ito) and rapidly activating delayed rectifier current (IKr). Epi showed no 
significant effect on Ito (Figure 17). IKr was slightly attenuated by Epi, but 
largely suppressed by Pheny (Figure 18). Pheny failed to change the channel 








Figure 17. Transient outward currents (Ito) in the presence of phenylephrine. 
hiPSC-CMs were treated for 1 h with vehicle (Control) or 100 µM phenylephrine 
(Pheny). 4-AP (3 mM), an inhibitor of Ito, was used to separate Ito from other currents. 
(A-B) Representative current traces in hiPSC-CMs treated with vehicle (Control) or 
phenylephrine (Pheny) in the absence and presence of 4-AP. (C) I-V curves of 
4-AP-sensitive currents (Ito) in hiPSC-CMs treated with vehicle (Control) or 
phenylephrine (Pheny). (D) Mean values of Ito at 40 mV in absence (Control) and 
presence (Pheny) of phenylephrine. “n” represents number of cells. 
 
 
Figure 18. Rapidly activating delayed rectifier K channel currents (IKr) in the 
presence of epinephrine and phenylephrine. hiPSC-CMs were treated for 1 h with 
vehicle (Control) or 500 µM epinephrine or 100 µM phenylephrine. Cs+ instead of K+ 
was used as the charge carrier to record the Cs+ currents conducted by HERG 





vehicle (Control) or epinephrine (Epi) or phenylephrine (Pheny). (B) I-V curves of IKr in 
each group. (C) Activation curves of IKr in each group. (D) Mean values of IKr at -30 
mV in each group. (E) The potentials at 50 % activation (V0.5) of IKr in each group. “n” 
represents number of cells. *p<0.05 versus Control. 
 
3.12. The hiPSC-CMs from a second (D2) and third (D3) donor 
recapitulated some key results in cells from the first donor (D1) 
Considering that all the experiments described above were performed in 
hiPSC-CMs from one healthy donor (D1), some important experiments were 
repeated in hiPSC-CMs from another two subjects (D2 and D3). The results 
showed that in both D2 (Figure 19) and D3 (Figure 20) hiPSC-CMs, the alpha 
1-adrenoceptor activator phenylephrine changed AP parameters in the same 
manner as in D1 cells. Also, as in D1 cells, the alpha 2-adrenoceptor agonist 
clonidine did not influence APs. Both the positive (significant effects) and 
negative (no effects) results obtained in D1-hiPSC-CMs were successfully 










Figure 19. hiPSC-CMs from the second donor mimicked results obtained in 
hiPSC-CMs from the first donor.  A second donor (D2) was recruited and 
hiPSC-CMs were generated (D2-hiPSC-CMs). Experiments were carried out under 
the same conditions as that in D1 cells. The cells were treated with either vehicle 
(Control) or 100 µM phenylephrine (Pheny) or 100 µM clonidine. (A) Representative 
AP-traces of a cell from each group.  (B) Averaged values of APD10. (C) Averaged 
values of APD50. (D) Averaged values of APD90. (E) Averaged values of Vmax. (F) 
Averaged values of APA.  (G) Averaged values of resting potential (RP). The 
numbers given in B represent the number of cells for B-G.  *p<0.05 versus Control 








Figure 20. hiPSC-CMs from the third donor mimicked results obtained in 
hiPSC-CMs from the first donor.  A third (D3) donor was recruited and hiPSC-CMs 
were generated (D3-hiPSC-CMs). Experiments were carried out under the same 
conditions as that in D1 cells. The cells were treated with either vehicle (Control) or 
100 µM phenylephrine (Pheny) or 100 µM clonidine. (A) Representative AP-traces of 
a cell from each group.  (B) Averaged values of APD10. (C) Averaged values of 
APD50. (D) Averaged values of APD90. (E) Averaged values of Vmax. (F) Averaged 
values of APA.  (G) Averaged values of resting potential (RP). The numbers given in 
B represent the number of cells for B-G.  *p<0.05 versus Control according to 











4.1. Main findings and the importance of the study 
To our knowledge, this is the first study using hiPSC-CMs to investigate the 
roles and mechanisms of alpha 1-adrenoceptor signaling for the ion channel 
dysfunction, APD-prolongation and occurrence of arrhythmias caused by toxic 
effects of high concentration of catecholamine. The novel findings in this study 
include (i) high concentration of epinephrine can prolong APD through 
activating alpha 1-adrenoceptors in hiPSC-CMs; (ii) high concentration 
epinephrine can trigger arrhythmias through activating alpha 1-adrenoceptors 
in hiPSC-CMs; (iii) ROS signaling contributes to APD-prolongation induced by 
activating alpha 1- adrenoceptors in hiPSC-CMs; (iv) NADPH oxidases are 
involved in effects of alpha 1-adrenoceptor activation in hiPSC-CMs; (v) PKC 
acts as a downstream factor of ROS in alpha 1-adrenoceptor activation; (vi) Na, 
L-type Ca and HERG channel dysfunctions contribute to AP-changes caused 
by alpha 1-adrenoceptor activation in hiPSC-CMs.   
Takotsubo cardiomyopathy is a unique acute cardiac attack and occurs 
predominantly in postmenopausal women in association with emotional or 
physical stress or administration of catecholamines such as epinephrine [22, 
60, 61]. Although the pathological changes in heart of TTC-patients are 
generally reversible when appropriate treatment is carried out, the in-hospital 
mortality rate of TTC is similar to that of acute coronary syndromes [11]. The 
primary manifestation may occur with different complications containing 
ventricular tachyarrhythmias. According to reported data, the prevalence of 
arrhythmias such as ventricular tachycardia, ventricular fibrillation and 
atrioventricular nodal block can reach 14% of TTC-cases, mainly in the setting 
of long QTc [62]. When TTC-patients suffered from arrhythmias, the long-term 





prolongation [64], so exploring the pathogenic mechanisms of QT prolongation 
in the setting of TTC is clinically relevant.  
So far it has been well established that catecholamine excess may play a 
central role in the pathogenesis of TTC. The beta-adrenoceptor, especially 
beta1-receptor, is the most important adrenoceptor in cardiomyocytes and 
most studies on the pathogenesis of TTC focused on beta-adrenoceptor 
signaling. However, some clinical studies showed that some TTC-patients did 
not profit from beta-blocker treatment. Furthermore, animal studies 
demonstrated that combination of alpha-blocker and beta-blocker improved the 
efficacy of treatments against TTC-phenotypic changes. Taken all together, 
alpha-adrenoceptor activation in the setting of TTC may play an important role 
for pathogenesis of TTC, but studies on roles of alpha-adrenoceptor signaling 
for TTC remain spars. The study on roles of alpha-adrenoceptor signaling for 
long QTc and arrhythmogenesis in TTC is still lacking. This study revealed that 
high concentration of catecholamine can enhance ICa-L and reduced IKr via 
alpha1-receptor signaling, leading to APD-prolongation (equivalent to 
QT-prolongation in patients) and arrhythmic events. The study provided ionic 
and molecular mechanisms for understanding the occurrence of long QTc and 
arrhythmias in the setting of TTC or other cardiac disorders related with toxic 
catecholamine effects. Furthermore, this study may also provide novel 
information for the therapy of TTC or other heart diseases associated with 
catecholamine excess. 
4.2. Possible mechanisms underlying AP-changes and arrhythmias 
induced by toxic catecholamine via alpha-adrenoceptor activation 
The fact that TTC is usually triggered by stress, under which sympathetic 
activity is enhanced and catecholamine release is elevated [65], suggests 
roles of catecholamine excess for the incidence of arrhythmias or heart failure. 





wall-motion abnormality in left ventricle, the important clinical feature of TTC, 
provided a hint for studies. It has been shown that the sympathetic innervation 
in the basal myocardium is higher than that in the apex. On the contrary, the 
ß-adrenoceptor (ß-AR) density is higher in apical than in basal myocytes [66]. 
Thus, the apical cells may response to catecholamine more strongly than 
basal myocytes. Indeed, several studies showed that isoprenaline exerts 
stronger effect on apical than basal cardiomyocytes in the left ventricle [67-69]. 
These data indicate that the high ß-AR density plays a critical role for the 
regional cardiac dysfunction and happening of TTC.  
Here, another question to be addressed is how catecholamine exerts a 
negative inotropic effect. It has been shown that ß2-AR can couple to 
Gs-adenylate cyclase-cAMP or Gi or non-G-protein pathways [70, 71]. When 
catecholamine concentration is high, ß2-AR mainly couples to Gi protein, 
which can suppress the cardiac contraction through reducing intracellular 
cAMP level [27, 72]. Thus, the negative inotropic effect in apical myocytes is 
relatively larger than that in basal myocytes, leading to increased outflow 
resistance of the ventricular blood and resulting in a ballooning change of 
ventricle. Whether arrhythmias in TTC are also associated with the regional 
difference of sympathetic nerve innervations and adrenoceptor distributions is 
still unknown. Whether the -adrenoceptor mediated signaling plays an 
important role for APD-prolongation and appearance of arrhythmias in TTC is 
so far unclear.  
In the present study, to test our hypothesis that -adrenoceptor signaling may 
play roles for arrhythmias caused by toxic effects of catecholamine, we 
investigated the possible contributions of -adrenoceptor signaling to the 
acquired LQT and arrhythmogenesis in the setting of TTC (high concentration 
of catecholamine). We used a high concentration of epinephrine (Epi), which is 





-adrenoceptors, and different -adrenoceptor blockers or activators for the 
study. Epi prolonged APD and reduced Vmax of APs. An -adrenoceptor 
blocker, phentolamine (blocking alpha 1-and alpha 2-receptor), reversed the 
effects of epinephrine, implying that alpha-adrenoceptor signaling contributes 
to effects of epinephrine. To confirm the involvement and subtype of 
-adrenoceptors in the observed effects, more specific agonists and 
antagonists of -receptors were applied. Phenylephrine (mainly activates 
alpha1-receptors) but not clonidine (mainly activates 2-receptors) mimicked 
the Epi-effects and prazosin (1-receptor specific blocker) abolished the 
effects of phenylephrine, indicating that 1-adrenoceptor activation contributed 
to the changes of APs in presence of high doses of catecholamine. 
Ample clinical evidence has demonstrated that excessive prolongation of the 
action potential duration (APD) may lead to ventricular tachyarrhythmia [73]. 
The APD-prolongation reflects the QT-prolongation on ECG in patients and is 
the culprit for occurrence of arrhythmias in long QT-syndrome. In contractile 
myocytes , APs are triggered by the acute entrance of sodium ions (Na+) 
inside the cell, resulting in an inward current (INa) that shifts the membrane 
potential from its resting state to a depolarization state [74], which evokes a 
contraction of the cardiomyocyte through “Excitation-Contraction Coupling”. 
The maximal velocity (Vmax) of the depolarization is critical for the speed of 
excitation conduction. The reduction of Vmax of APs may decelerate electrical 
pulse propagation and cause conduction defect in the heart. Both changes 
(the APD-prolongation and suppression of Vmax) detected in the presence of 
high concentration epinephrine are substrates for occurrences of arrhythmias. 
Our study, indeed, detected that arrhythmic events were induced by 
epinephrine and were attenuated by the -adrenoceptor blocker, indicative of 
the involvement of -adrenoceptor signaling in occurrence of arrhythmias in 
the setting of TTC. In the presence of Epi, more cells showed arrhythmic 





showing arrhythmic events, suggesting that the -blocker only reduced but did 
not terminate the arrhythmic events in most cells. Epi slightly slowed cell 
beating, probably representing a toxic effect of high concentration of 
catecholamine. 
Previous studies have shown that reactive oxygen species (ROS) are not only 
toxic by-products of aerobic metabolism, but also can be used as intracellular 
signaling molecules in vascular cells [75]. Excessive production of ROS 
causes oxidative stress, which relates to many cardiovascular diseases [76]. 
To further explore the signal factors related to alpha-receptor activation, we 
checked ROS production. Actually, our data demonstrated that alpha-receptor 
activation also contributes to the enhancement of ROS production induced by 
catecholamine. We observed that (1) the -adrenoceptor blocker reduced Epi 
induced ROS generation; (2) an antioxidant, N-acetyl-L-cysteine (NAC, a ROS 
blocker) blocked the effects of Epi and Pheny on APs; (3) Hydrogen peroxide 
H2O2 (a form of endogenous ROS) mimicked Epi and Pheny effects on APs. 
These data demonstrated an important role of ROS for AP-changes 
associated with -adrenoceptor activation. 
The next question is how the ROS-level was elevated by -adrenoceptor 
activation. To figure it out, we tried to use inhibitors for NADHP oxidases, 
which are known to be important for ROS generation. Actually, the NADPH 
oxidase blocker DPI attenuated the effects of Pheny, implying that NADPH 
oxidases were in the signaling responsible for AP changes evoked by 
-adrenoceptor activation. How NADPH oxidases were activated and whether 
other ROS-linked signaling were involved in -adrenoceptor activation need to 
be assessed in further studies. 
Previous studies have shown that the 1-adrenoceptor is coupled to 
phospholipase C and PKC [77, 78]. Then we examined the possible 





the toxic effects of catecholamine. To unveil PKC effects in -adrenoceptor 
activation, both PKC blocker and activator were employed. The PKC-blocker 
(chelerythrine) inhibited the effects of both Epi and Pheny and the PKC 
activator (PMA) mimicked their effects on APs, which confirmed a role of PKC 
activation for -adrenoceptor mediated effects. With respect of the 
mechanisms underlying PKC activation, the existence of 1-adrenoceptor and 
Gq in hiPSC-CMs may help us understand it as that the activation of 
1-receptor stimulates Gq protein and then stimulates PLC, which initiates its 
downstream signaling including PKC activation. Although the Gq-PLC-PKC 
signaling is a well-known and typical pathway for Gq-coupled receptors, we 
found that PKC is a downstream factor of ROS because the PKC blocker 
abolished the ROS effect. Given that NADPH oxidases were also involved in 
effects of 1-receptor activation because its inhibitor (DPI) blocked the effects 
of phenylephrine, we can interpret the signaling in 1-adrenoceptor activation 
by high concentration of catecholamine as; 
1-adrenoceptor-Gq-PLC-NADPH-ROS-PKC. Here how PLC evokes NADPH 
oxidase activation is still an open question and further studies are needed to 
answer it.  
Ion-channel dysfunctions are associated with numerus cardiac disorders 
including Long QT syndrome (LQTS) [79]. The normal rhythm of the heart 
results from the regular electrical activity based on transmembrane currents 
conducted by different ion channels in cardiomyocytes [74]. The most 
important currents are INa, ICa-L and potassium currents. The modification of ion 
channels may lead to electrical instability and predisposition to ventricular 
arrhythmias. Therefore, we researched the ionic mechanism underlying the 
AP-changes induced by alpha-adrenoceptor activation. 
To test our another hypothesis that 1-adrenoceptor signaling may contribute 





channel currents were assessed in the presence of high concentration of 
epinephrine and -adrenoceptor agonist or antagonist. 
The peak INa was suppressed by epinephrine and reversed by the 
alpha-receptor blocker. Likewise, the 1-receptor agonist (Pheny) inhibited INa, 
hinting at a modulation SCN5A channels by 1-adrenoceptor signaling. The 
facts that Pheny did change the channel gating kinetics and the 
-adrenoceptor blocker failed to reverse the Epi-effect on the channel 
inactivation suggest that the suppression of INa did not result from changes of 
sodium channel gating kinetics. Of note, the influence of epinephrine on 
SCN5A expression (a reduction) was consistent with its effect on peak INa. All 
data together showed that -adrenoceptor activation changes mainly the 
channel expression level. The suppression of INa can explain reduction of 
Vmax of APs.  
The L-type Ca channel currents (ICa-L) were enhanced by alpha-receptor 
signaling through enhancing the channel activation, which was confirmed by 
the evidences that Epi increased ICa-L and the -receptor blocker reduced Epi 
effects and additionally, Pheny mimicked Epi effects. The expression level of 
L-type Ca channel (CACNA1C) was also increased, which is in agreement 
with ICa-L enhancement and suggests that alpha-receptor signaling regulated 
both the channel activity and expression level. The enhancement of ICa-L is in 
agreement with the APD-prolongation. 
The hERG (human ether-a-go-go related gene) channel (Kv11.1) underlying the 
rapid component of delayed rectifier potassium current (IKr) is critical for the 
repolarization of cardiomyocytes and a blockade of hERG channels can 
produce an excessive prolongation of action potential duration [80]. Moreover, 
hERG channel is the target of many drugs that exert either therapeutic or side 
effects in the heart. We observed that toxic doses of catecholamine 





reduced HERG channel current (IKr). Reduced IKr can prolong APD and 
contribute to occurrence of arrhythmic events. Therefore, the suppression of IKr 
by 1-receptor activation may contribute to APD/QT prolongation and 
arrhythmogenesis of TTC or other cardiac disorders caused by toxic effects of 
catecholamine. 
Some other currents that may contribute to AP morphology including the 
transient outward current (Ito) and Na+/Ca2+ exchanger current (INCX) were also 
assessed. Both currents were only slightly enhanced by Epi or Pheny and the 
enhancement did not reach statistical significance, suggesting the role of Ito 
and INCX for the arrhythmogenesis in -adrenoceptor activation is negligible. 
This is different from -adrenoceptor activation. In our previous study, we 
observed that isoprenaline (activating -receptors rather than -receptors) 
significantly suppressed Ito [57], suggesting a contribution of Ito to 
APD-prolongation induced by -receptor activation.  
Here a next question is how the Na (SCN5A), L-type Ca (CACNC1C) and 
HERG (IKr) channels were regulated by 1-adrenoceptor activation. The 
mechanisms behind the modulation of these channels may be complex 
because many factors linked to the signaling of 
1-receptor-Gq-PLC-NADPH-ROS-PKC figured out in this study may 
participate in the modulation of these channels. For example, ROS and PKC 
are known as important regulators of different ion channels [81-83]. Whether 
ROS and PKC can directly or indirectly (through other downstream factors) 
regulate the three types of channels, and more importantly, whether they 
mediate the suppression of the SCN5A and HERG and the enhancement of 
L-type Ca channel currents and expression levels when 1-adrenoceptors are 
activated, need to be investigated by further studies. 
Taken together, the study demonstrated that alpha 1-receptor activation 





changing their channel gating or expression in cardiomyocytes. The ion 
channel dysfunctions led to abnormal APs (reduction of Vmax and 
prolongation of APD) and hence facilitated occurrence of arrhythmic events, 
suggesting a possible responsibility of alpha 1-receptor signaling for 
occurrence of arrhythmias in high concentration of catecholamine. The toxic 
effects of catecholamine excess contained the effects of the 1-adrenoceptor 
mediated signaling, 1-Gq-PLC-NADPH-ROS-PKC. The results from this 
study confirmed our hypothesis that alpha-adrenoceptor signaling may play an 
important role for arrhythmogenesis under circumstances of catecholamine 
excess. This information may help clinical doctors to think about application of 
alpha-blockers for treatment of TTC or heart diseases associated with 
catecholamine excess, especially when beta-blocker is contraindicated or 
alone not effective in the treatment. 
Although it has been widely accepted that the toxic effects of catecholamine 
may be a main cause for TTC, other heart diseases may be also influenced by 
catecholamine effects. It is well-known that catecholamine and adrenoceptor 
activation may contribute to some heart diseases, likes chronic heart failure, 
hypertrophic cardiomyopathy, catecholaminergic polymorphic ventricular 
tachycardia (CPVT), arrhythmogenic right ventricular cardiomyopathy (ARVC), 
etc. Therefore, the current study may also have implications for those and 
other cardiac disorders or arrhythmias that are associated with catecholamine 
effects. 
4.3. Conclusion 
This study demonstrated that the alpha 1-adrenoceptor signaling is important 
for the toxic effects of catecholamine excess. High concentration 
catecholamine can activate alpha 1-receptor besides beta-receptors and 
cause ion channel dysfunctions, abnormal action potentials and arrhythmias 





alpha-blocker can be a possible option for treating arrhythmias in the setting of 
TTC or other cardiac disorders associated with catecholamine effects.  
4.4. Study limitations 
Alpha 1-adrenoceptor contains several subtypes such as α1A, α1B und α1D.This 
study did not clarify which subtype was responsible for observed result.  
The study demonstrated that alpha1-receptor activation evoked at least three 
intracellular signaling, NADPH oxidases, ROS and PKC. Although our data 
clarified that PKC is a downstream factor of ROS, the alpha1-receptor related 
signaling responsible for the activation of NADPH oxidases was not revealed. 
Which factors modulated the Na, Ca and HERG channels were not clarified. In 
addition, PKC contain more than 10 subtypes. The subtype-specific effects 
were not investigated, so the subtypes of PKC responsible for the observed 
effect are unknown. 
The hiPSC-CMs possess differences comparing with adult human 
cardiomyocytes. We cannot rule out the possibility that some intracellular 
signaling in hiPSC-CMs is different from that in adult human cardiomyocytes. 
Besides, hiPSC-CMs from TTC-patients were not used for this study. Whether 
hiPSC-CMs from TTC-patients display different results remain unknown.  
The concentration of epinephrine (500 µM) used in this study is much higher 
than catecholamine concentration in TTC-patients because the sensitivity of 
hiPSC-CMs to catecholamine is lower than adult human cardiomyocytes. The 
possibility that native cardiomyocytes differentially response to catecholamine 
in patients cannot be excluded.  
The hiPSC-CMs in this study were derived from only three healthy donors and 
most experiments were performed in cells from one donor. The possibility that 





From a statistical point of view, the results from this study should not be 
interpreted as that from the whole population, which should be taken into 
consideration while extrapolating the data. 
5. SUMMARY  
Takotsubo cardiomyopathy (TTC) is characterized by a transient regional wall 
motion abnormality with clinical manifestations similar to that of an acute 
coronary syndrome. Acquired long QT syndrome (LQTs) and life-threatening 
arrhythmias are common complications of TTC. Both clinical and experimental 
data suggested an involvement of signaling mediated by 
non-beta-adrenoceptors in the pathogenesis of TTC. Toxic catecholamine 
effect has been widely accepted as a main cause for pathogenesis of TTC. 
Therefore, we investigated the importance of alpha-adrenoceptor related 
signaling for the toxic effects of catecholamine, focusing on the mechanisms of 
LQTs and arrhythmias. 
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), 
which were generated from human skin fibroblasts of three healthy donors, 
were treated with toxic concentration of epinephrine (Epi, 0.5 mM for 1h) or 
phenylephrine (Pheny, 0.1 mM for 1 h) to mimic the setting of TTC. Different 
alpha-adrenoceptor agonists and antagonists were used to differentiate 
receptor-specific effects. Patch clamp, PCR, immunostaining and FACS 
techniques were employed for the study. 
High concentration of epinephrine (Epi) suppressed the depolarization velocity 
and prolonged the duration (APD) of action potentials (APs) and induced 
arrhythmic events in hiPSC-CMs. The Epi effects were attenuated by an alpha 
adrenoceptor blocker (Phentolamine). An alpha 1-adrenoceptor agonist 
phenylephrine (Pheny) but not an alpha 2-adrenoceptor agonist (clonidine) 





1-adrenoceptor signaling in APD-prolongation and arrhythmogenesis in the 
setting of TTC. Epi enhanced ROS-production, which could be attenuated by 
the alpha-adrenoceptor blocker. Treatment of cells with H2O2 (100 µM) 
mimicked the effects of Epi and Pheny on APs and a ROS-blocker (NAC, 1mM) 
prevented the Epi and Pheny effects, indicating that the ROS-signaling is 
involved in the alpha 1-adrenoceptor actions. DPI, an inhibitor of NADPH 
oxidases blocked the Pheny effects, implying that NADPH oxidases were 
involved in alpha 1-adrenoceptor signaling. A PKC-blocker (chelerythrine) 
suppressed the effects of Epi and Pheny, and a PKC stimulator mimicked the 
effects, implying that PKC participated in alpha 1-receptor signaling. In 
addition, the PKC-blocker inhibited the effects of H2O2, suggesting that PKC 
acted as a downstream factor of ROS. Epi or Pheny suppressed the peak 
sodium channel currents and rapidly activating rectifier K currents and 
enhanced the L-type Ca channel currents, which can explain the abnormal 
APs induced by alpha 1- adrenoceptor activation.  
The study demonstrated that the alpha 1-adrenoceptor signaling plays 
important roles for ion channel dysfunctions, long QT interval and 
arrhythmogenesis in the setting of catecholamine excess via 
1-adrenoceptor-NADPH-ROS-PKC related signaling. The application of 
alpha-blocker may be helpful for treating arrhythmias in some patients with 
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